1. A method for mining relationships between multimedia content and a plurality of devices, the method comprising:
receiving multimedia content information;
receiving device information; and
correlating the multimedia content information and the device information to determine a best-fit device to reproduce the multimedia content.
2. The method according to claim 1, wherein the relationships include parent child relationships between the plurality of devices.
3. The method according to claim 1, wherein the plurality of devices include wireless devices.
4. The method according to claim 1, wherein a best fit device is a group of devices of the plurality of devices capable of reproducing the content.
5. The method according to claim 1, wherein the relationships specify which device controls reproduction.
6. A computer system having a processor, a memory, and an operating environment, the computer system operable to execute the method recited in claim 1.
7. A computer-readable medium having computer-executable components, the computer-readable medium comprising:
a ranking component to assign values, indicating importance, to content and a plurality of devices;
a listening component to receive device offerings and content preferences and to compile the device offerings and the content preferences; and
a control component to specify a level of user intervention.
8. The computer-readable medium according to claim 7, further comprising:
an arbitration component to resolve device or content contention.
9. The computer-readable medium according to claim 7, wherein the ranking component assigns values based on business rules.
10. The computer-readable medium according to claim 7, wherein the level of user intervention is set to zero.
11. The computer-readable medium according to claim 7, wherein the listening component collects network environment data.
12. The computer-readable medium according to claim 8, wherein the arbitration component automatically selects a device to reproduce the content.
13. The computer-readable medium according to claim 8, wherein the arbitration component automatically selects content to be reproduced on a group of devices of the plurality of devices.
14. The computer-readable medium according to claim 12, wherein the arbitration component determines the precedence of the device using values assigned by the ranking component.
15. A communication network having a plurality of communication devices capable of transferring content wirelessly, the communication network comprising:
a first communication device to receive streaming content;
a second communication device to receive content different from the content streaming to the first communication device; and
a mediator to determine whether the streaming content should take precedence over the content different from the content streaming on the first communication device.
16. The communication network of claim 15, further comprising:
a third communication device that is connected to a non-intelligent device.
17. The communication network of claim 15, wherein the content different from the content streaming to the first communication device is a notification stream.
18. The communication network of claim 15, wherein the first communication device receives content from the Internet.
19. The communication network of claim 16, further comprising:
a fourth communication device that dynamically generates a user interface.
20. The communication network of claim 15, wherein the mediator is distributed across the first and second communication devices.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A transmucosal delivery device comprising a first layer and a second layer, wherein the first layer comprises a bioactive agent and the second layer comprises a pharmaceutically acceptable oxidizing agent.
2. The device of claim 1, wherein the device comprises a patch having a first surface and second surface, wherein the first layer is adjacent to the first surface of the patch, and the second layer is adjacent to the first layer.
3. The device of claim 2, wherein an additional first layer is adjacent to the second surface of the patch, and an additional second layer is adjacent to the additional first layer.
4. The device of claim 2, wherein the patch comprises a substantially impermeable material.
5. The device of claim 1, wherein the first layer and the second layer comprise a gel, a hydrogel, an acrylic polymer, a cellulose polymer, a polyurethane, a polylacticpolyglycolic acid, a polyamino acid, a polysaccharide, a polyurea, a polyvinyl alcohol, a polyvinylpyrrolidone (povidone), or any combination thereof.
6. The device of claim 1, wherein the first layer and second layer are separated by a removable separating layer.
7. The device of claim 1, further comprising a third layer comprising a pharmaceutically acceptable oxidizing agent, wherein the first layer is between the second layer and third layer.
8. The device of claim 7, wherein the first layer is adjacent to the second layer and third layer.
9. The device of claim 7, wherein the first layer and second layer are separated by a first removable separating layer, and the first layer and third layer are separated by a second removable separating layer.
10. The device of claim 1, wherein the first layer and second layer comprises a biocompatible polymer.
11. The device of claim 1, wherein the device comprises a capsule, and the capsule comprises a core comprising the first layer and a second layer adjacent to the core.
12. The device of claim 1, wherein the bioactive agent comprises a peptide or a protein.
13. The device of claim 1, wherein the bioactive agent comprises a peptide or protein, and the peptide or protein comprises insulin, calcitonin, vasopressin, luteinizing hormone-releasing hormone, leuprolide, thyrotropin-releasing hormone, cholecystokinin, alpha-interferon, beta-interferon, gamma-interferon, human growth hormone, alpha-1-transforming growth factor, beta-1-transforming growth factor, granulocyte colony stimulating factor (G-CSF), granulocyte macrophage colony stimulating factor (G-MCSF), parathyroid hormone (PUT), glucagons, somatostatin, vase-active intestinal peptide (VIP); anti-cytokines, nutriceutical agents or any combination thereof.
14. The device of claim 1, wherein the pharmaceutically acceptable oxidizing agent comprises iodine, povidone-iodine, any source of iodine or combinations of oxidants, silver protein, active oxygen, potassium permanganate, sulfonamides, or any combination thereof.
15. The device of claim 1, further comprising a mucosal penetration enhancer incorporated into the first layer, the second layer, or any combination thereof.
16. The device of claim 15, wherein the mucosal penetration enhancer comprises dimethyl sulfoxide, anionic surfactants, urea’s, fatty acids, fatty alcohols, terpenes, cationic surfactants, nonionic surfactants, zwitterionic surfactants, polyols, amides, lactam, acetone, alcohols, sugars or any combination thereof.
17. The device of claim 1, wherein the amount of bioactive agent is from 1% to 95% and the amount of pharmaceutically acceptable oxidizing agent is from 1 to 90%.
18. A pharmaceutical composition comprising a bioactive agent, a pharmaceutically acceptable oxidizing agent, and a pharmaceutically acceptable carrier.
19. The composition of claim 18, wherein the pharmaceutically acceptable carrier comprises a gel, a hydrogel, an ointment, a solution, a paste, a powder, an absorbent gauze, a spray, a patch, a capsule or any combination thereof.
20. The composition of claim 18, wherein the bioactive agent comprises insulin and the pharmaceutically acceptable oxidizing agent comprises iodine.
21. A kit comprising (a) comprising a bioactive agent on a first pharmaceutically acceptable carrier and (b) a pharmaceutically acceptable oxidizing agent on a second pharmaceutically acceptable carrier.
22. A method of delivering a bioactive agent to a subject comprising at least one mucosal membrane, the method comprising applying the delivery device of claim 1 to the mucosal membrane.
23. The method of claim 22, wherein the mucosal membrane is located within the nasal cavity, the mouth, gums, lips, cheeks, underneath the tongue, the rectum, or the vagina.
24. The method of claim 22, further comprising applying sonophoresis, iontophoresis, electrophoresis, electroosmosis, vibroacoustic force, or a combination thereof to the mucosal membrane either before or after contacting the mucosal membrane with the delivery device.
25. A method of delivering a bioactive agent to a subject comprising at least one mucosal membrane using the kit of claim 21, the method comprising contacting the mucosal membrane with (1) a pharmaceutically acceptable oxidizing agent on a second pharmaceutically acceptable carrier followed by (2) contacting the mucosal membrane with the bioactive agent on a first pharmaceutically acceptable carrier.
26. A method for treating a subject with diabetes comprising applying the delivery device of claim 1 to at least one mucosal membrane in the subject, wherein the bioactive agent comprises insulin and the pharmaceutically acceptable oxidizing agent comprises iodine.
27. The method of claim 26, wherein the device further comprises a mucosal penetration enhancer comprising dimethyl sulfoxide, anionic surfactants, ureas, fatty acids, fatty alcohols, terpenes, cationic surfactants, nonionic surfactants, zwitterionic surfactants, polyols, amides, lactam, acetone, alcohols, sugars, or any combination thereof in the first layer, second layer, or both first and second layer.